Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05162508
Other study ID # APHP211494
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date December 16, 2021
Est. completion date January 16, 2026

Study information

Verified date August 2023
Source Assistance Publique - Hôpitaux de Paris
Contact Nicolas DE PROST, MD-PHD
Phone 0149878506
Email nicolas.de-prost@aphp.fr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Background:The impact of the emergence of SARS-CoV-2 variants on the severity and clinical outcomes of COVID-19 is controversial. Whether virological characteristics including the mutational patterns of the different viral proteins (e.g., Spike, NSP proteins, ORF6) could be associated with a different immune response and subsequent severity of the disease is unknown. ln the next coming months, new variants carrying the same or new mutational patterns will continue to emerge. Monitoring their dynamics over time and their impact on disease severity is required for refining national and international disease control policies. Main objective: To unravel the relationships between specific viral mutations/mutational patterns and the clinical outcomes of COVID-19 in patients hospitalized in intensive care units (ICUs) for acute respiratory failure following severe SARS-CoV-2 infection. Design of the study Prospective multicentre observational cohort study Schedule for the study: Inclusion period: 24 months; Participation period: 28 days ; Total duration : 24 months + 28 days;


Description:

Background:The impact of the emergence of SARS-CoV-2 variants on the severity and clinical outcomes of COVID-19 is controversial. Preliminary studies estimated that the probability of death associated with variant of concern (VOC) B.1.1.7, the UK variant, is 55% higher than that associated with pre-existing variants. However, no difference has been found in another study. In Brazil, infection with VOC P1 has been suggested to be associated with an increased case fatality rate in young adults. The effect of other "variants of concern" (Beta, B.1.351; Delta, B.1.617.2, or the most recent Omicron variants) or "variants of interest" (A27, B.1.525, etc.) on the severity of the disease and the prognosis of severe forms is unknown. More generally, whether virological characteristics including the mutational patterns of the different viral proteins (e.g., Spike, NSP proteins, ORF6) could be associated with a different immune response and subsequent severity of the disease is unknown. ln the next coming months, new variants carrying the same or new mutational patterns will continue to emerge in different geographic areas, as a result of the collective immune pressure induced by natural infection and vaccination. Monitoring their dynamics over time and their impact on disease severity is required for refining national and international disease control policies. In this project, a large prospective multicenter observational cohort promoted by the Assistance Publique-Hôpitaux de Paris (AP-HP) will be conducted, to understand the effect of SARS-CoV-2 genetic variability on the outcome of COVID-19 disease in patients with severe illness. The study will include critically ill patients hospitalized for acute respiratory failure/acute respiratory distress syndrome (ARDS) associated with COVID-19. The objective of the work will be to characterize the SARS-CoV-2 variants found in this population over time, and to identify and phenotypically characterize specific mutations/mutational patterns associated with the different clinical outcomes (primary clinical endpoint defined as mortality at day-28). The impact of the mutations on viral infectivity, sensitivity to neutralizing antibodies and ability to induced cytokine production will be assessed in vitro and ex-vivo respectively, in appropriate models available in the laboratory. Further to full-length viral genome sequencing, our in-house shotgun metagenomics method will be used to characterize the effect of SARS-CoV-2 variations on respiratory transcriptomic expression profiles and the relationship with the clinical evolutionary profiles. Design of the study Prospective multicentre observational cohort study Main objective: To unravel the relationships between specific viral mutations/mutational patterns and the clinical outcomes of COVID-19 in patients hospitalized in intensive care units (ICUs) for acute respiratory failure following severe SARS-CoV-2 infection. Schedule for the study: Inclusion period: 24 months; Participation period: 28 days ; Total duration : 24 months + 28 days;


Recruitment information / eligibility

Status Recruiting
Enrollment 2000
Est. completion date January 16, 2026
Est. primary completion date January 16, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age = 18 years. - Availability of nasopharyngeal swab from SOC - SARS-CoV-2 infection as assessed by a positive RT-PCR test (CT < 32), including in SARS CoV-2 vaccinated or previously infected patients - Patient admitted in the ICU for acute respiratory failure (SpO2 = 90% and need for supplemental oxygen or any kind of ventilator support; i.e., OMS 10-category ordinal scale =5) - Patient or trusted person or close or relative, And, accepting study participation Exclusion Criteria: - Patient with SARS-CoV-2 infection but no acute respiratory failure - Patient deprived of liberty or under legal protection (guardianship, curators, legal protection, forced hospitalization)

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Nasopharyngeal swab
Nasopharyngeal swab available in Standard Of Care (SOC) will be analysed (Full-length SARS-CoV-2 RNA sequencing and Transcriptomic analyses)

Locations

Country Name City State
France Assistance Publique Hôpitaux de Paris - CHU HENRI MONDOR Créteil Val De Marne

Sponsors (1)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Day-28 vital status vital status (living / deceased) at Day-28 after admission in intensive care units (ICUs) for acute respiratory failure following severe SARS-CoV-2 infection
See also
  Status Clinical Trial Phase
Completed NCT04979858 - Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask N/A
Recruiting NCT05311410 - Viral Kinetics of SARS-CoV-2 in Patients With COVID-19 in the Intensive Care Unit Undergoing Dental Procedures N/A
Active, not recruiting NCT05073718 - SARS-CoV-2 and Acetylsalicylic Acid (SARA) Phase 3
Completed NCT05055505 - The School SPIT Study - Elementary Schools in Low COVID-19 Incidence Regions N/A
Completed NCT05055492 - The School SPIT Study - Elementary Schools in High COVID-19 Incidence Regions N/A
Completed NCT05060510 - The School SPIT Study - COVID-19 Testing in Secondary Schools N/A
Completed NCT05054218 - COVID-19 Immunogenicity of a Third Dose of mRNA-1273 Vaccine Among Cancer Patients
Completed NCT05449392 - Topical Antibacterial Agents for Prevention of COVID-19 Phase 1
Completed NCT05076253 - Efficacy of Ivermectin in COVID-19 Phase 1/Phase 2
Recruiting NCT05172024 - Understanding the Long-term Impact of COVID-19 in Adults (RECOVER)
Terminated NCT05593770 - International Sites: Novel Experimental COVID-19 Therapies Affecting Host Response Phase 2/Phase 3
Completed NCT05030974 - RECOVAC Repeated Vaccination Study Phase 4
Withdrawn NCT05067946 - Evaluation of Efficacy, Safety and Immunogenicity of GX-19N in Healthy Individuals Who Have Received COVID-19 Vaccines Phase 2/Phase 3
Not yet recruiting NCT05013034 - Exploratory Regimen of Basiliximab for Treatment of Pulmonary Cytokine Storm in SARS-CoV-2 Hospitalized Adult Patients Phase 2
Withdrawn NCT05393999 - SABRE: A Single-arm Prospective Study Measuring Safety and Tolerability of SARS-CoV-2 Neutralising Antibodies in High-risk Populations Phase 2
Recruiting NCT05047783 - Masitinib in Patients With Symptomatic Mild to Moderate COVID-19 Phase 2
Not yet recruiting NCT05116657 - Obstructive Sleep Apnoea Post Covid 19: Role of the Upper Airway Microbiome
Recruiting NCT04590222 - Impact of a Monoamine Oxidase Inhibitor on the Phenotype of Blood Mononucleated Cells in Patients With COVID-19
Completed NCT04551911 - Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19 Phase 2
Completed NCT04953039 - Use of Saliva for COVID-19 Diagnosis